The high-quality equity of listed companies has become fragrant. From October 16 to 17, 2021, the Fifth Intermediate People's Court of Chongqing Municipality, on the Taobao judicial auction network platform, auctioned 13.3 million shares of Chongqing Laimei Pharmaceutical Co., Ltd. (Laimei Pharmaceutical 300006) held by Tibet Laimei Pharmaceutical Investment Co., Ltd. (Tibet Laimei Pharmaceutical) and 24.76 million shares of Laimei Pharmaceutical held by Qiu Yu, totaling about 38.06 million shares, and finally all of them were successfully auctioned, with a total transaction price of 252.9 million yuan and a transaction price equivalent to 6.64 yuan per share.
Zhang Yu, a natural person, took about 33.63 million shares this time, spending about 223.44 million yuan, plus 13 million shares auctioned on October 10, Zhang Yu spent a total of 312.13 million yuan and 46.63 million shares.
The upstream news reporter learned that the reason why the shares held by the shareholders were judicially auctioned was that the shareholder Qiu Yu triggered a default clause due to the stock pledge repurchase business of the Export-Import Bank of China, and the Export-Import Bank of China applied to the Fifth Intermediate People's Court of Chongqing Municipality for compulsory enforcement. Shareholder Tibet Laimei triggered a default clause in the share pledge repurchase business of Sichuan Trust Co., Ltd., and Sichuan Trust Co., Ltd. applied to the Fifth Intermediate People's Court of Chongqing Municipality for compulsory enforcement.
Zhang Yu took about 33.63 million shares this time
The Fifth Intermediate People's Court of Chongqing Municipality divided the shares of Chongqing Laimei Pharmaceutical held by Tibet Laimei and the shares of Laimei Pharmaceutical held by Qiu Yu into 7 subjects, totaling about 38.06 million shares, and conducted a public auction.
The starting price of the lot totaled 252 million yuan, and the final transaction price totaled about 252.9 million yuan.
Among them, Tibet Laimei held 4,435,126 shares of Laimei Pharmaceutical, with a starting price of 29,362,308,180 yuan and a transaction price of 29,462,308,180 yuan. There were 3 buyers who paid the deposit to enter the market, and finally after 2 bids, one of which was delayed, Zhang Beilong auctioned it for 29.46230818 million yuan, and the transaction price was 100,000 yuan higher than the starting price.
Tibet Laimei holds 4,435,125 shares of Laimei Pharmaceutical, with a starting price of 29,362,301,550 yuan and a transaction price of 30,162,301,550 yuan. The 5 buyers each paid a deposit to enter the market, and finally after 8 bids, of which 7 were delayed, Zhang Yu auctioned it for 30.16230155 million yuan, and the transaction price was 800,000 yuan higher than the starting price.
Tibet Laimei held 4,435,125 shares of Laimei Pharmaceutical, with a starting price of 29,362,301,550 yuan, 3 people registered, and Zhang Yu auctioned it at a starting price of 29,362,301,550 yuan.
The 24.76 million shares of Laimei Pharmaceutical held by Qiu Yu were auctioned in four auctions, all of which were 6.19 million shares, with a starting price of 40.980276 million yuan, and in the 4 auctions, Zhang Yu was auctioned at a starting price of 40.980276 million yuan.
In this way, Zhang Yu took a total of about 33.63 million shares, spending about 223.44 million yuan. Together with the 13 million shares auctioned on October 10, Zhang Yu spent a total of 312.13 million yuan and took 46.63 million shares, accounting for 4.42% of the total share capital of Laimei Pharmaceutical, with an average price equivalent to 6.69 yuan per share.
According to the auction announcement, the starting price is 20% lower by the average closing price of the 20 trading days before the auction date of the stock multiplied by the total number of shares (4435126 shares).
On October 18, Chongqing Laimei Pharmaceutical reported closing at 6.61 yuan, an increase of 17.89%, and a turnover rate of 10.65%.
Previously, there were 6 transactions of Laimei Pharmaceutical shares
According to the Tianyancha APP, Laimei Pharmaceutical was established on September 6, 1999 and listed in 2009, as one of the first 28 GEM enterprises, with a registered address at No. 99 Yuma Road, Nan'an District, Chongqing, with the legal representative being Peng Weimin and a registered capital of 1,055,911,205 yuan.
On September 10, 2021, Laimei Pharmaceutical issued a pre-disclosure announcement that Qiu Yu, a shareholder holding more than 5% of the company's shares, and tibet Laimei, a shareholder holding more than 5% of the company's shares, and tibet Laimei, a shareholder with a total of more than 5% of the company's shares, will hold a public auction in 18 public auctions on the Taobao judicial auction network platform from October 9 to 10, 2021 and October 16 to 17, 2021, respectively.
From October 9 to 10, the court held 61 million shares (accounting for 5.78% of the company's total share capital) held by Qiu Yu and Tibet Laimei in 11 public auctions, of which 6 auctions were sold and 5 auctions were streamed. Among them, Zhang Yu, a natural person, spent 44.3638 million yuan on two occasions and auctioned two 6.5 million shares, totaling 13 million shares. Zhang Hongzhi spent 44.3638 million yuan to auction 6.5 million shares, and Bi Xuefen spent 34.126 million yuan in three times, taking 3 5 million shares, a total of 15 million shares.
After the completion of the auction, the company's shares directly held by Qiu Yu will be reduced to 164.84 million shares, accounting for 15.61% of the company's total share capital; the company's shares held by Tibet Laimei will be reduced to 33.305376 million shares, accounting for 3.15% of the company's total share capital.
From October 16, 2021 to October 17, 2021, the court conducted a public auction of 38,065,375 shares (representing 3.6% of the total share capital of the company) held by Qiu Yu and Tibet Laimei in seven public auctions. All seven public auctions were sold.
After the completion of the auction, the company's shares directly held by Qiu Yu will be reduced to 140.08 million shares, accounting for 13.27% of the company's total share capital; the company's shares held by Tibet Laimei will be reduced to 20 million shares, accounting for 1.89% of the company's total share capital.
The actual controller of the company is still the Guangxi State-owned Assets Supervision and Administration Commission
For the auction, Laimei Pharmaceutical said that after the completion of the transfer of shares in the first and current judicial auction transactions, the total number of voting shares owned by Zhongheng Group and its co-actors was 420,064,953 shares, accounting for 39.78% of the company's total share capital, the company's controlling shareholder is still Zhongheng Group, the actual controller of the company is still Guangxi State-owned Assets Supervision and Administration Commission, and the results of this judicial auction will not lead to changes in the company's controlling shareholders and actual controllers, and will not have a significant impact on the company's governance structure and continuous operation.
In the first half of 2021, Laimei Pharmaceutical's operating income was 612 million yuan, an increase of 2.23% year-on-year; the net profit attributable to the shareholders of the listed company was 323.927 billion yuan, an increase of 499.74% year-on-year, turning losses into profits; and basic earnings per share were 0.03 yuan.
Liu Yong, chief reporter of upstream news, intern Zhang Luyu